Noxopharm Ltd has released a press release.
Company Announcement Regarding Appendix 3Y Disclosures
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Noxopharm
- Appendix 4D and Half Year Financial Report
- LuPIN Survival Outcome Confirmed by Conference Presentation
- Major Survival Benefit in Prostate Cancer Patients Announced
- Noxopharm Dec 2020 Quarterly Activities Report & Appendix 4C
- NOXCOVID Study Advances
Later from Noxopharm
- Noxopharm Receives A$4.59M Federal Gov R&D Tax Rebate
- NOXCOVID Trial Advances to Final Stage
- Noxopharm IONIC Immuno-Oncology Trial Commences
- Veyonda Patent Lodged for Major Septic Shock Opportunity
- Noxopharm Files Septic Shock Treatment Patent for Veyonda®
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm